Chronic obstructive pulmonary diseases (Miami, Fla.) · 2026
Isoflavone Intake is Associated With Decreased Chronic Obstructive Pulmonary Disease Morbidity.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Belz Daniel C, Quiroz Ernesto, Woo Han, Jackson Mariah K, Putcha Nirupama, Fawzy Ashraf, Lorizio Wendy, Hanson Corrine K, Hansel Nadia N
Аннотация
INTRODUCTION: Isoflavones, phenolic compounds in legumes and soy products, are linked to reduced risk of chronic diseases such as coronary heart disease. However, effects on respiratory diseases like chronic obstructive pulmonary disease (COPD) are understudied.
METHODS: Former smokers with COPD were enrolled in a prospective cohort study. Morbidity was assessed at baseline, 3, and 6 months using the COPD Assessment Test (CAT), Clinical COPD Questionnaire (CCQ), modified Medical Research Council (mMRC), St George’s Respiratory Questionnaire (SGRQ), Ease of Cough and Sputum Clearance (ECSC), and exacerbation history. Spirometry and biomarkers of platelet activation, inflammation, and oxidative stress were obtained. Dietary intake was assessed via a food frequency questionnaire, with total isoflavone intake calculated as the sum of genistein, daidzein, glycitein, formononetin, and biochanin A. Associations were analyzed with generalized estimating equation regression analysis and adjusted for baseline covariates.
RESULTS: A total of 99 participants (mean age 66.4, 55% female, 41% White, and a baseline forced expiratory volume in 1 second percentage predicted of 49.8%) had a mean isoflavone intake of 1.8mg (standard deviation [SD]=3.1). One SD increase in total isoflavone intake was associated with lower CAT (β=–2.0, p=0.011), CCQ (β=–0.2, p=0.029), and ECSC (β=–0.70, p <0.001) scores, and 7.4% lower urinary 11-dehydro-thromboxane B2 (p=0.047). A trend toward better SGRQ scores was observed but was not significant. Isoflavones were not associated with mMRC or exacerbations.
CONCLUSION: Increased isoflavone intake was associated with improved respiratory morbidity and reduced platelet activation, suggesting a potential dietary pathway influencing COPD morbidity.
METHODS: Former smokers with COPD were enrolled in a prospective cohort study. Morbidity was assessed at baseline, 3, and 6 months using the COPD Assessment Test (CAT), Clinical COPD Questionnaire (CCQ), modified Medical Research Council (mMRC), St George’s Respiratory Questionnaire (SGRQ), Ease of Cough and Sputum Clearance (ECSC), and exacerbation history. Spirometry and biomarkers of platelet activation, inflammation, and oxidative stress were obtained. Dietary intake was assessed via a food frequency questionnaire, with total isoflavone intake calculated as the sum of genistein, daidzein, glycitein, formononetin, and biochanin A. Associations were analyzed with generalized estimating equation regression analysis and adjusted for baseline covariates.
RESULTS: A total of 99 participants (mean age 66.4, 55% female, 41% White, and a baseline forced expiratory volume in 1 second percentage predicted of 49.8%) had a mean isoflavone intake of 1.8mg (standard deviation [SD]=3.1). One SD increase in total isoflavone intake was associated with lower CAT (β=–2.0, p=0.011), CCQ (β=–0.2, p=0.029), and ECSC (β=–0.70, p <0.001) scores, and 7.4% lower urinary 11-dehydro-thromboxane B2 (p=0.047). A trend toward better SGRQ scores was observed but was not significant. Isoflavones were not associated with mMRC or exacerbations.
CONCLUSION: Increased isoflavone intake was associated with improved respiratory morbidity and reduced platelet activation, suggesting a potential dietary pathway influencing COPD morbidity.